Anti-IL17/ IL17A/ CTLA-8 functional antibody
Anti-IL17/ IL17A/ CTLA-8 functional antibody for cell culture, ELISA & in-vivo assay
Go to IL17/IL17A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T22095-Ab-1/ GM-Tg-hg-T22095-Ab-2 | Anti-Human IL17/IL17A monoclonal antibody | Human |
GM-Tg-rg-T22095-Ab-1/ GM-Tg-rg-T22095-Ab-2 | Anti-Rat IL17/IL17A monoclonal antibody | Rat |
GM-Tg-mg-T22095-Ab-1/ GM-Tg-mg-T22095-Ab-2 | Anti-Mouse IL17/IL17A monoclonal antibody | Mouse |
GM-Tg-cynog-T22095-Ab-1/ GM-Tg-cynog-T22095-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IL17/IL17A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T22095-Ab-1/ GM-Tg-felg-T22095-Ab-2 | Anti-Feline IL17/IL17A monoclonal antibody | Feline |
GM-Tg-cang-T22095-Ab-1/ GM-Tg-cang-T22095-Ab-2 | Anti-Canine IL17/IL17A monoclonal antibody | Canine |
GM-Tg-bovg-T22095-Ab-1/ GM-Tg-bovg-T22095-Ab-2 | Anti-Bovine IL17/IL17A monoclonal antibody | Bovine |
GM-Tg-equg-T22095-Ab-1/ GM-Tg-equg-T22095-Ab-2 | Anti-Equine IL17/IL17A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T22095-Ab-1/ GM-Tg-hg-T22095-Ab-2; GM-Tg-rg-T22095-Ab-1/ GM-Tg-rg-T22095-Ab-2; GM-Tg-mg-T22095-Ab-1/ GM-Tg-mg-T22095-Ab-2; GM-Tg-cynog-T22095-Ab-1/ GM-Tg-cynog-T22095-Ab-2; GM-Tg-felg-T22095-Ab-1/ GM-Tg-felg-T22095-Ab-2; GM-Tg-cang-T22095-Ab-1/ GM-Tg-cang-T22095-Ab-2; GM-Tg-bovg-T22095-Ab-1/ GM-Tg-bovg-T22095-Ab-2; GM-Tg-equg-T22095-Ab-1/ GM-Tg-equg-T22095-Ab-2 |
Products Name | Anti-IL17/IL17A monoclonal antibody |
Format | mab |
Target Name | IL17 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-IL17 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T22095 |
Target Name | IL17 |
Gene ID | 3605,16171,301289,708123,481837,101095339,282863,100034142 |
Gene Symbol and Synonyms | CTLA-8,CTLA8,IL-17,IL-17A,IL17,IL17A,ILA17 |
Uniprot Accession | Q16552,Q61453,Q687Y7 |
Uniprot Entry Name | IL17_HUMAN,IL17_RAT,IL17_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
Disease | Cancer |
Gene Ensembl | ENSG00000112115 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: IL17, gene name: IL17A, also named as CTLA-8, CTLA8, IL-17, IL-17A, IL17. This gene is a member of the IL-17 receptor family which includes five members (IL-17RA-E) and the encoded protein is a proinflammatory cytokine produced by activated T cells. IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides, and remodeling proteins. The encoded protein elicits crucial impacts on host defense, cell trafficking, immune modulation, and tissue repair, with a key role in the induction of innate immune defenses. This cytokine stimulates non-hematopoietic cells and promotes chemokine production thereby attracting myeloid cells to inflammatory sites. This cytokine also regulates the activities of NF-kappaB and mitogen-activated protein kinases and can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). IL-17A plays a pivotal role in various infectious diseases, inflammatory and autoimmune disorders, and cancer. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The lung damage induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to a large extent, a result of the inflammatory response promoted by cytokines such as IL17A. [provided by RefSeq, Sep 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.